BCI researcher part of team shortlisted for Cancer Grand Challenges awards
23rd June 2021
Dr Benjamin Werner from Barts Cancer Institute, Queen Mary University of London, is part of an international team that has been selected to share its ideas on how to solve one of cancer’s toughest challenges.
Read moreBCI academic receives prestigious science learning award
17th June 2021
Congratulations to Professor Fran Balkwill from Barts Cancer Institute, Queen Mary University of London, who has been announced as the 2021 winner of the Beetlestone Award, which recognises leadership and legacy in the field of informal science learning.
Read moreStudy suggests blood test could guide precision treatment in bladder cancer
16th June 2021
A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led by Professor Tom Powles from Barts Cancer Institute at Queen Mary University of London and Barts Health NHS Trust. The findings from the study, published today in Nature, may change our understanding of cancer care following surgery.
Read moreBuilding a human tumour microenvironment in the lab
15th June 2021
Researchers from Barts Cancer Institute at Queen Mary University of London, led by Professor Fran Balkwill and Dr Oliver Pearce, have built two 3D multi-cellular models of the human tumour microenvironment (TME) in ovarian cancer. The models, which are the first created from the CanBuild project, have revealed novel insights into the role of the TME in cancer progression.
Read moreScreening for ovarian cancer did not reduce deaths
13th May 2021
A large-scale randomised trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier, according to results published in The Lancet.
Read moreImpact of COVID-19 in patients with HBP conditions in East London
12th May 2021
Researchers from Barts Cancer Institute at Queen Mary University of London have conducted a population-based study to explore the risk factors associated with COVID-19 susceptibility and survival in patients with a history of diseases of the liver, pancreas or biliary system – also known as hepato-pancreato-biliary (HPB) diseases – in East London.
Read more